HAYA Therapeutics SA’s $65 Million Series A Funding Round

Lenz & Staehelin acted for Eli Lilly; Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital; VISCHER acted for HAYA Therapeutics AG. Wilson Sonsini Goodrich &…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here